Eli Lilly & Co, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the stock and has a $900.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman’s rating is based on Eli Lilly & Co’s promising growth prospects and strategic positioning in the pharmaceutical industry. Despite competitive pressures from Novartis’ Kisqali, which has shown robust growth in the CDK4/6 inhibitor market, Seigerman remains optimistic about Lilly’s overall performance.
Seigerman highlights that Lilly’s diabetes segment is expected to drive sustained growth, supported by the company’s strong pipeline strategy. Additionally, the recent approval of donanemab is seen as a positive development, enhancing Lilly’s position in the market. The company’s oncology franchise is also anticipated to contribute positively to its financial performance, reinforcing the Buy rating.
In another report released yesterday, TR | OpenAI – 4o also upgraded the stock to a Buy with a $885.00 price target.